GZ-793A is a selective inhibitor of vesicular monoamine transporter 2 (VMAT2), which transports the monoamine neurotransmitters from cellular cytosol into synaptic vesicles. GZ-793A is 50-fold selective for VMAT over the serotonin or dopamine transporters. VMAT2 has recently been considered a target for the treatment of methamphetamine abuse. In rat studies, GZ-793A decreased self-administration of methamphetamine with no development of tolerance.
GZ-793A is a selective inhibitor of vesicular monoamine transporter 2 (VMAT2).
Neuroblastoma, the most common extracranial solid malignancy among children, originates from undifferentiated neural crest cells (NCC). Despite recent intensified treatment, high-risk patients still have a high mortality rate. To explore a new therapeutic strategy, we performed an integrated genomic and
Questions
Reviews
★★★★★ No rating value
Active Filters
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.